ReviewJournal of translational medicine2017
Implementation of longevity-promoting supplements and medications in public health practice: achievements, challenges and future perspectives.
Review in Journal of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Dietary supplement use in longevity: evidence from 2,877 centenarians.GeroScience · 2026Article
- Gerontology lost in translation from demography to biology of aging and back.Biogerontology · 2026Review
- Metabolic regulation of behavior by the intestinal enzyme FMO-2.Science advances · 2025Article
- Bridging expectations and science: a roadmap for the future of longevity interventions.Biogerontology · 2025Review
- Vaccine hesitancy in patients with COVID-19 who have back pain.Osong public health and research perspectives · 2023Article
- The Funding Channels of Geroscience.Cold Spring Harbor perspectives in medicine · 2023Review
- The association between chronic heart failure and frailty index: A study based on the National Health and Nutrition Examination Survey from 1999 to 2018.Frontiers in cardiovascular medicine · 2022Article
- Article
- Method and Computer System for Dialog Optimization of Aging Biomarker Panels for Biological Age Assessment.Frontiers in genetics · 2021Article
- Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.Advances in experimental medicine and biology · 2021Article
- In Vivo Anti-Inflammatory Effects and Related Mechanisms of Processed Egg Yolk, a Potential Anti-Inflammaging Dietary Supplement.Nutrients · 2020Article
- Insights into the Role of Bioactive Food Ingredients and the Microbiome in Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2020Review
- Phenotypic Screening inPharmaceuticals (Basel, Switzerland) · 2020Review
- Astaxanthin as a Putative Geroprotector: Molecular Basis and Focus on Brain Aging.Marine drugs · 2020Review
- The stress field ages: A close look into cellular aging processes.Psychoneuroendocrinology · 2020Article
- Review
- Anise HyssopFrontiers in physiology · 2020Article
- Unveiling the Role of Inflammation and Oxidative Stress on Age-Related Cardiovascular Diseases.Oxidative medicine and cellular longevity · 2020Review
- Aging: therapeutics for a healthy future.Neuroscience and biobehavioral reviews · 2020Review
- Molecular therapies delaying cardiovascular aging: disease- or health-oriented approaches.Vascular biology (Bristol, England) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost modern societies undergo rapid population aging. The rise in life expectancy, nevertheless, is not accompanied, to date, by the same increment of healthspan. Efforts to increase healthspan by means of supplements and pharmaceuticals targeting aging-related pathologies are presently in spotlight of a new branch in geriatric medicine, geroscience, postulating that aging could be manipulated in such a way that will in parallel allow delay the onset of all age-associated chronic disorders. DISCUSSION: Currently, the concept of the "longevity dividend" has been developed pointed out that the extension of healthspan by slowing the rate of aging is the most efficient way to combat various aging-related chronic illnesses and disabling conditions than combating them one by one, what is the present-day approach in a generally accepted disease-based paradigm. The further elaboration of pharmaceuticals specifically targeted at age-associated disorders (commonly referred to as 'anti-aging drugs') is currently one of the most extensively developed fields in modern biogerontology. Some classes of chemically synthesized compounds and nutraceuticals such as calorie restriction mimetics, autophagy inductors, senolytics and others have been identified as having potential for anti-aging intervention through their possible effects on basic processes underlying aging. In modern pharmaceutical industry, development of new classes of anti-aging medicines is apparently one of the most hopeful directions since potential target group may include each adult individual. Implementation of the geroscience-based approaches into healthcare policy and practice would increase the ratio of healthy to unhealthy population due to delaying the onset of age-associated chronic pathologies. That might result in decreasing the biological age and increasing the age of disability, thus increasing the age of retirement and enhancing income without raising taxes. Economic, social and ethical aspects of applying the healthspan- and lifespan-promoting interventions, however, have to be comprehensively debated prior to their implementation in public health practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.